SYRE Earnings & Financial Statements
Spyre Therapeutics, Inc.
$83.73
+$3.83(+4.79%)
43
Overall
60
Value
50
Tech
21
Quality
Market Cap
$7.13B
Volume
299.40K
52W Range
$15.86 - $110.18
Target Price
$118.60
SYRE earnings and financial statements: Spyre Therapeutics, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
SYRE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | - | - | $886.0K | $2.33M | $18.74M |
| Operating income | -$209.56M | -$208.57M | -$242.30M | -$84.78M | -$65.65M |
| EBITDA | -$165.22M | -$207.97M | -$354.30M | -$81.99M | -$64.07M |
| Net income | -$155.20M | -$208.02M | -$338.79M | -$83.81M | -$65.80M |
| EPS (diluted) | $-1.98 | - | $-49.12 | $-24.75 | $-25.00 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $777.78M | $608.48M | $341.86M | $71.14M | $109.93M |
| Total liabilities | $62.55M | $90.68M | $73.29M | $20.84M | $25.98M |
| Shareholders’ equity | $715.24M | $517.80M | $184.02M | $50.30M | $83.94M |
| Cash and equivalents | $85.72M | $89.42M | $188.89M | $34.86M | $15.14M |
| Long-term debt | - | - | - | $4.00M | $4.61M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.14M | -$53.72M |
| Capital expenditure | $7.00M | - | $15.47M | -$38.0K | -$573.0K |
| Free cash flow | -$169.25M | -$157.41M | -$99.91M | -$80.18M | -$54.29M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | SYRE | $83.73 | +4.8% | 299.40K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Spyre Therapeutics, Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW